Affymetrix News

Affymetrix, the Santa Clara maker of tools used to study DNA and diagnose diseases, was sued for patent infringement by the Massachusetts Institute of Technology over the company's GeneChip system used to ...

Clinical Data Inc. , a Newton developer of targeted therapeutics and genetic tests, reports that the European Patent Office has granted the firm's German subsidiary a patent for a genetic biomarker linked to a ...

Consumer genome testing companies Navigenics Inc. and 23andMe, co-owned by the wife of Google co-founder Sergey Brin, refused orders of the California Health Department to cease accepting clients by continuing ...

The state Health Department ordered direct-to-consumer genome testing companies Navigenics Inc.

Main Category: Breast Cancer Also Included In: Cancer / Oncology Article Date: 02 Jun 2008 - 14:00 PDT Affymetrix Inc.

Stephen C. Holmes is joining as counsel in the firm's Silicon Valley office. The team comes to Dewey & LeBoeuf from Affymetrix, Inc., a leading Silicon Valley biotechnology company.

“With its industry-leading performance and low genotyping cost, the Affymetrix SNP Array 6.0 is helping researchers around the world discover genetic causes of many complex diseases and then validate the findings across a larger sample population.”

Justin O'Kelly, 408-731-5991 PR Manager, Corporate Communications Doug Farrell, 408-731-5285 Vice President, Investor Relations Affymetrix Inc. via PR-inside.com

For the first time since the company he co-founded went public in 1996, Affymetrix Chief Executive Stephen Fodor bought its shares on the open market. via San Jose Mercury News

Mike Klein, 760-597-9236 mklein@perceptaassociates.com Today Percepta Associates Inc. via PR-inside.com

“Traditional tools used to identify tumors of uncertain origin include imaging, such as CT scans and MRIs, as well as thorough pathological evaluation with immunohistochemistry and other techniques”

The new test aids in the diagnosis of tumors of uncertain origin and is among the first microarray-based diagnostic tests for cancer available in . via Rehab Management

“Shares won't rally meaningfully for several months, until investors' visibility is improved”

Affymetrix Inc., maker of the Gene Chip, lost one-third of its value Tuesday after the company said revenue from its gene-based research tools would be lower than expected because drug developers and other ... via SF Gate

Movie rental chain Blockbuster Inc. offered more than $1 billion for Circuit City Stores Inc. via Boston Globe

That's gotta hurt. After Affymetrix lowered its 2008 revenue guidance by about 3% yesterday evening, to a range of $490 million to $510 million, its stock opened more than 35% lower today. via Fool.com

“We are using the SNP 6.0 arrays to obtain the most comprehensive profile of genomic abnormalities aimed at discovering novel molecular targets”

This Tuesday during the early hours of trading, Affymetrix was down 36.37 percent with a volume over 12,700,000. On Tuesday, April 15th, 2008, Affymetrix Inc. via M2.com

“Working closely with a global leader such as Affymetrix provides us with access to industry-leading technology and some of the world's most prominent genetic researchers”

Mar 24, 2008 - Affymetrix Inc. today announced that it has signed an agreement with Avesthagen Limited, a leading biotechnology company based in Bangalore, India. via Med Ad News

“Affymetrix is consolidating its manufacturing operations to further increase operational efficiencies, enabling us to remain more competitive in the marketplace”

West Sacramento biotech company began cuts last week Sacramento Business Journal - by Celia Lamb Staff writer Dennis McCoy Sacramento Business Journal Affymetrix owns 170,000 square feet of office and ... via Bizjournals

“We are very pleased to have the Affymetrix Cytogenetic Solution in our laboratory”

Affymetrix Inc. recently announced the full commercial launch of its complete Cytogenetic Solution, which combines the high-density SNP Array 6.0 with a simple assay and intuitive software. via Pharmaceutical Online

Mar 13, 2008 - Roche NimbleGen Inc., a company of Roche Applied Science, and Affymetrix Inc. via Med Ad News

Affymetrix, Inc. today announced that company management will provide a corporate overview at two upcoming financial conferences. via Earth Times

The sequencing of the human genome made many scientific experiments possible, but the biochips made by Affymetrix and Illumina are the real muscle behind many of those experiments. via The Motley Fool